GPCR Targeting Stocks

Biotechnology firms in this sector focus on G protein-coupled receptors (GPCRs), a massive class of membrane proteins that mediate the majority of physiological responses to hormones and neurotransmitters.

As of Oct 23, 2026, GPCR Targeting has 6 US-listed companies worth $4B combined. The median member moved -0.7% over the past week; SEPN led at +11.2% and XCUR trailed at -6.3%.

Companies in GPCR Targeting

• SEPN – Septerna, Inc. Common Stock, $1.8B
• GPCR – Structure Therapeutics Inc. American Depositary Shares, $1.6B
• TECX – Tectonic Therapeutic, Inc., $444M
• OKYO – OKYO Pharma Limited, $77.1M
• XCUR – Exicure Inc, $7.3M
• TRVN – Trevena Inc, $57,010

Related groups

• Pain Management
• Drug Discovery
• Clinical Stage Biotech
• Metabolic Disorders
• Biotechnology
• Healthcare
• Biopharmaceutical
• Clinical Stage Biopharma

All equity groups